tbuckley/cabot-search huggingface dataset:
749P ANV419, a selective IL-2R-beta-gamma targeted antibody-IL-2 fusion protein, in patients with advanced solid tumors, a phase I/II study
Authors: H. Läubli, G. Alonso, J.S. Lopez, E. Calvo, M. Joerger, V. Perez, D. Di Blasi, A. Nair, K. Richter, C. Huber, J. Mouton, S. Costanzo, S. Jethwa, C.M. Bucher, E. Garralda
Journal: Annals of Oncology (2022)
126P The HLA I composite score and VHIO immune gene-expression signature (VIGex) as selection tools to explore the tumor microenvironment (TME) in patients (pts) treated with immunotherapy (IT)
Authors: O. Saavedra Santa Gadea, M. Vila Casadesus, O. Mirallas, A.H. Calvo, F.J. Ros Montana, I. Baraibar Argota, C. Suarez Rodriguez, A. Oberoi, R. Morales Barrera, P. Iranzo Gomez, G. Alonso, I. Brana, A. Cabrera Navarro, E. Hernández-Illán, M. Vieito Villar, M.E. Elez Fernandez, M. Gonzalez Rodriguez, E. Felip, E. Garralda, A. Vivancos
Journal: Annals of Oncology (2022)
932MO Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816
Authors: E. Felip, C. Wang, T-E. Ciuleanu, G. Saylors, F. Tanaka, K-N. Chen, H. Ito, N. Girard, S. Lu, M. Provencio Pulla, T. Mitsudomi, M. Awad, P.M. Forde, R. Lawrance, F. Taylor, G. Worthy, S.I. Blum, L. Vo, J.L. Cai, J. Spicer
Journal: Annals of Oncology (2022)
412P Phase I study of intraperitoneal irinotecan in combination with standard systemic chemotherapy in patients with extensive peritoneal metastases of colorectal origin: The INTERACT trial
Authors: R.A.G. Van Eerden, N.L. De Boer, J.P. van Kooten, C. Bakkers, M.V. Dietz, G-J.M. Creemers, S.M. Buijs, R. Bax, F.M. de Man, R.J. Lurvink, M. Diepeveen, A.R.M. Brandt-Kerkhof, E. van Meerten, S.L. Koolen, I.H.J.T. de Hingh, K. Verhoef, R.H. Mathijssen, P.W.A. Burger
Journal: Annals of Oncology (2022)
135MO HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522
Authors: R.A. Dent, J. Cortés, L. Pusztai, H.L. McArthur, S. Kuemmel, J. Bergh, C. Denkert, Y.H. Park, R. Hui, N. Harbeck, M. Takahashi, M. Untch, P.A. Fasching, F. Cardoso, A. Haiderali, L. Jia, A.M. Nguyen, W. Pan, J. O'Shaughnessy, P. Schmid
Journal: Annals of Oncology (2022)
795P A phase Ib trial of neoadjuvant oncolytic virus OrienX010 (ori) and anti-PD-1 toripalimab (tori) combo in patients (pts) with resectable stage IIIb-IV (M1a) acral melanoma
Authors: X. Wei, X. Wang, X. Bai, C. Li, L. Mao, Z. Chi, B. Lian, T. Bixia, Y. Kong, J. Dai, R.H.I. Andtbacka, J. Guo, C-L. Cui, L. Si
Journal: Annals of Oncology (2022)
261P Liquid biopsy–based biomarkers for the characterization of hormone receptor-positive (HR+) HER2-Low metastatic breast cancer (mBC)
Authors: L. Bortot, D. Basile, L. Palmero, A. Dri, L. Cucciniello, S. Buriolla, B. Pastò, R. Mazzeo, M. Bonotto, S. Bolzonello, A. Franzoni, L. Allegri, B. Belletti, G. Damante, L. Gerratana, A.M.M. Minisini, F. Puglisi
Journal: Annals of Oncology (2022)
305P The role of surgery in addition to chemotherapy in the second-line treatment of glioblastomas
Authors: A.S. Mendes, H. Pereira, P.C. Liu, H.M. Miranda, R.M. Romao, C. Noronha, L. Rocha, C. Pinheiro, E.M. Rosendo, M.J. Freitas Magalhães, R. Moreira, M.J. Pereira Amorim, M. Sousa, T. Malheiro Sarmento, A.M. Ferreira Araujo
Journal: Annals of Oncology (2022)
743P A phase Ib dose escalation study of CD137 mAb agonist OC-001 as monotherapy in patients with advanced or metastatic cancer
Authors: W.H. Miller, D. Provencher, Q.S-C. Chu, D. Jonker, A.M. Oza, G. Batist, R. Jamal, R. Goel, J.F. Hilton, J. Spratlin, P. Smith, I. Darling, J. Stille, C. Fortier, R. Mangat, J. Polzer
Journal: Annals of Oncology (2022)
52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC)
Authors: A. Vogel, S. Boeck, O. Waidmann, M. Bitzer, P. Wenzel, S. Belle, C. Springfeld, K. Schulze, A. Weinmann, U. Lindig, C. Trautwein, T. Dechow, F. Lammert, R. Plentz, C-H. Koehne, V. Kunzmann, M. Maenz, M.M. Kirstein, A. Saborowski
Journal: Annals of Oncology (2022)
739P Patient preference for subcutaneous nivolumab (NIVO) with/without recombinant human hyaluronidase PH20 (rHuPH20) vs intravenous NIVO: An exploratory analysis of a phase I/II pharmacokinetic multi-tumor study
Authors: S. Lonardi, B.M. Bennett, M. Dixon
Journal: Annals of Oncology (2022)
755P B7H3-targeted tri-specific killer engagers deliver IL-15 to NK cells but not T-cells, and specifically target solid tumors as a pan-tumor antigen strategy mediated through NK cells
Authors: J.S. Miller, N. Zorko, A. Merino, G. Phung, M. Khaw, P. Howard, H. Hamsher, Z. Davis, F. Cichocki, G.I. Berk, M. Felices
Journal: Annals of Oncology (2022)
670P Discordant pathologic tumor response in primary tumors and lymph nodes after neoadjuvant immune checkpoint inhibition (ICI) in head and neck squamous cell carcinoma (HNSCC)
Authors: A. Luginbuhl, E. Scott, L. Harshyne, E. Flerova, M. Tuluc, S. Gargano, J.M. Curry, D. Cognetti, A. Argiris, J.M. Johnson
Journal: Annals of Oncology (2022)
352P Mutations of SMAD4 and FBXW7 predict poor outcome in TP53-driven metastatic colorectal cancer
Authors: S. Lahoz, A. Rodriguez Hernandez, L. Fernandez-Mañas, T. Gorria, R.M. Zambrano, F.M. Esposito, T. Sauri Nadal, D.S. Pesantez Coronel, G. Riu, M. Cuatrecasas, P. Jares, L. Pedrosa, E. Pineda, A. Postigo, A. Castells, A. Prat, J. Maurel, J. Camps
Journal: Annals of Oncology (2022)
865P TNFRSF1B gene variants on susceptibility, clinicopathological aspects, and prognosis of patients with cutaneous melanoma
Authors: C.S. Passos Lima, B.F. Carvalho, G.V.B. Gomez, J. Carron, L. Traldi Macedo, G.M. Gonçalves, V.L. Vazquez, S.V. Serrano, G.J. Lourenço
Journal: Annals of Oncology (2022)
240P Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases
Authors: M. Bottosso, G. Griguolo, L. Sinoquet, M.C. Guarascio, V. Aldegheri, F. Miglietta, C. Barbieri, F. Girardi, W. Jacot, V. Guarneri, A. Darlix, M.V. Dieci
Journal: Annals of Oncology (2022)
483P Pre-clinical and early clinical assessment of the safety and anti-tumor activity of RP12146, a PARP1/2 inhibitor in solid tumors
Authors: P. Tomczak, M. Kwiatek, D. Chraniuk, M. Kmiecik, I. Lugowska, M. Chełstowska, S. Eleswarapu, S. Veeraraghavan, K. Routhu, P. Barde, A. Nair
Journal: Annals of Oncology (2022)
278O Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295
Authors: J.L. Campian, O. Butt, J. Huang, J. Luo, Y. Tao, R. Strowd, D. Hissim, S.H. Kizilbash, C. Abraham, G. Ansstas, T. Johanns, A. Kim, M. Ciorba, M. Chheda
Journal: Annals of Oncology (2022)
1032P ML41256: Phase II study of atezolizumab (atezo) in combination with bevacizumab (beva) in advanced non-squamous non-small cell lung cancer (nsqNSCLC) patients (pts) pretreated with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs)
Authors: W.F. Fang, J. Fang, P. Tian, Y. Fan, Q. Yu, X. Zhang, Z. Wang, L. Zhang
Journal: Annals of Oncology (2022)
1011P MET and NF2 alterations confer early resistance to first-line alectinib treatment in ALK-rearranged non-small cell lung cancer
Authors: J. Hu, N. Ding, Y. Chen, J. Liu, J. Zhou, X. Xu, H. Bao, Y. Song, D. Zhang, Y. Shao, Y. Zhang
Journal: Annals of Oncology (2022)
133O Extended adjuvant aromatase inhibition after sequential endocrine therapy: Final results of the phase III DATA trial
Authors: V.C.G. Tjan-Heijnen, S.W.M. Lammers, S.M.E. Geurts, I.J.H. Vriens, A.C.P. Swinkels, C.H. Smorenburg, M. van der Sangen, J.R. Kroep, H. de Graaf, A.H. Honkoop, F.L.G. Erdkamp, W.K. de Roos, S.C. Linn, A.L.T. Imholz
Journal: Annals of Oncology (2022)
TCT-482 Clinical Outcomes for Patients With Cardiogenic Shock and Subsequent Transcatheter Aortic Valve Replacement: An Analysis of the National Inpatient Sample 2012 to 2019
Authors: Yaser Khalid, Fizan Khalid, Kirti Dasu, Rafail Beshai, Neethi Dasu
Journal: Journal of the American College of Cardiology (2022)
186P Evaluation of event-free survival as a surrogate for overall survival in early-stage triple-negative breast cancer following neoadjuvant therapy
Authors: P.A. Fasching, M. Huang, A. Haiderali, W. Xue, W. Pan, V. Karantza, F. Yang, J. Truscott, Y. Xin, J. O'Shaughnessy
Journal: Annals of Oncology (2022)
954P Cemiplimab with platinum-based chemotherapy (chemo) for first-line (1L) locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 3 subgroup analysis
Authors: E. Kalinka-Warzocha, M. Gogishvili, T. Makharadze, M. Dvorkin, K.D. Penkov, K. Laktionov, M. Nechaeva, I. Rozhkova, X. He, R. Quek, J-F. Pouliot, F. Seebach, I. Lowy, G. Gullo, P. Rietschel
Journal: Annals of Oncology (2022)
461P Overview of patients inclusions and outcomes into modern phase I trials at Gustave Roussy over the last 5 years, OVATION study
Authors: E. Alouani, A. Gazzah, S. Mercier, R. Bahleda, A. Hollebecque, J-M. Michot, C. Baldini, S. Champiat, A. Marabelle, S. Postel-Vinay, V. Ribrag, Y. Loriot, S. Ponce, L. Mahjoubi
Journal: Annals of Oncology (2022)
357P Novel potential predictive biomarker to immunotherapy (Io) treatment in metastatic colorectal cancer (mCRC) patients: The role of the VHIO immune gene-expression signature (VIGex)
Authors: N. Saoudi Gonzalez, M. Vila Casadesus, F.J. Ros Montana, I. Baraibar Argota, F. Salvà Ballabrera, A. Garcia Rodriguez, D.E. López Valbuena, D. Gómez-Puerto, A. Hernando-Calvo, J. Tabernero, A. Vivancos, M.E. Elez Fernez
Journal: Annals of Oncology (2022)
654MO High dimensional immuno-phenotyping of immunotherapy response in head and neck cancer
Authors: K.J. O'Byrne, N. Ma, H. Sadeghirad, N. Jhaveri, J. Monkman, A. Pratapa, B. Ben Cheikh, R. Ladwa, B.G.M. Hughes, O. Braubach, A. Kulasinghe
Journal: Annals of Oncology (2022)
253P Unmet need in heavily pre-treated patients with HR+/HER2- metastatic breast cancer (mBC) in the US: A ConcertAI analysis
Authors: A.G. Waks, M. Gharaibeh, N. Sjekloca, N. Poluparthi, A. Shah, E. Bergamaco, T. MacCannell, G. Leung, I. Ntalla, H. Oko-osi, S.M. Tolaney
Journal: Annals of Oncology (2022)
731MO A phase I trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors
Authors: G.J. Hanna, A. Hernando Calvo, V. Morris, R.D. Carvajal, P.K. Paik, D.P. Zandberg, J. Kaczmar, L. Niculescu, R. Reiners, D. Bohr, E. Gharakhani, R. Salazar, S. Bilic, P.L. Bedard
Journal: Annals of Oncology (2022)
257P Efficacy of pembrolizumab in pre-treated breast cancer harboring high mutational load 140-290 – results from the Drug Rediscovery Protocol (DRUP)
Authors: L.J. Zeverijn, B.S. Geurts, J.M. van Berge Henegouwen, L.R. Hoes, H. van der Wijngaart, G.F. de Wit, P. Roepman, A. Jansen, W. de Leng, V. van der Noort, A. Van Ommen-Nijhof, H. Gelderblom, H.M.W. Verheul, E.E. Voest
Journal: Annals of Oncology (2022)
711P Sintilimab combined with bevacizumab biosimilar as a conversion therapy in potentially resectable intermediate stage hepatocellular carcinoma (HCC): A phase II trial
Authors: H. Sun, None X. Zhu, Q. Gao, S. Qiu, Y. Shi, X. Wang, X. Huang, X. Yang, Y. Ji, None Y. Pang, Y. He, None Y. Xu, None M. Li, None J. Zhu, Y. Shen, None C. Huang, J. Zhou, J. Fan
Journal: Annals of Oncology (2022)
777TiP Phase I study of LYL797, a ROR1-targeted CAR T-cell therapy with genetic and epigenetic reprogramming for the treatment of advanced solid tumors
Authors: D.R. Spigel, H. Murthy, S. Chumsri, B.J. Ganguly, L. Gong, H. Hiraragi, E. Larsen, W. Liu, L. Martell, S. Zhu, I-M. Bornman, S. Fitzsimmons, E. Barnum, S. Christiansen, H. Gillenwater
Journal: Annals of Oncology (2022)
898P The safety and efficacy of surufatinib for the treatment of advanced neuroendocrine tumors: A prospective, multicenter, real-world study
Authors: J. Long, C. Wu, B. Hu, C. Tao, H. Gu, H. Dong, J. Yan, Z. Qi, C. Zhao, J. Zhou
Journal: Annals of Oncology (2022)
990P Osimertinib for RT-naïve CNS metastasis of EGFR mutation-positive NSCLC: Phase II OCEAN study (LOGIK 1603/WJOG 9116L), part of the first-line cohort
Authors: H. Yamaguchi, K. Wakuda, M. Fukuda, H. Kenmotsu, K. Ito, Y. Tsuchiya-Kawano, K. Tanaka, T. Harada, Y. Nakatani, S. Miura, T. Yokoyama, T. Nakamura, M. Izumi, A. Nakamura, S. Ikeda, K. Takayama, K. Yoshimura, K. Nakagawa, N. Yamamoto, K. Sugio
Journal: Annals of Oncology (2022)
977P Phase II study of brigatinib in patients with tyrosine kinase inhibitor (TKI)-naïve ROS1-rearranged advanced non-small cell lung cancer (NSCLC): Barossa cohort 1
Authors: R. Toyozawa, S. Niho, Y. Goto, T. Takahashi, K. Ohashi, H. Daga, H. Tanaka, Y. Hattori, M. Morise, J. Sakakibara-Konishi, M. Kodani, T. Ikeda, S. Matsumoto, K. Yoh, S. Nomura, K. Goto
Journal: Annals of Oncology (2022)
820P Nivolumab (NIVO) +/- relatlimab (RELA) or ipilimumab (IPI) for patients (pts) with advanced treatment-naïve or -refractory basal cell carcinoma (BCC)
Authors: K.M. Schenk, J.S. Deutsch, M.D. Schollenberger, W.H. Sharfman, P.N. Brothers, A. Pons, J.F. Scott, K. Bibee, J.M. Taube, S.L. Topalian, E.J. Lipson
Journal: Annals of Oncology (2022)
1039P Efficacy and safety of surufatinib (HMPL-012) as a third-line or further treatment for advanced non-small cell lung cancer (NSCLC)
Authors: Y. Zheng, F. Niu, P. Jiang, X. Zhu, J. Lin, X. Wu, L. Qin, Z. Liu, S. Fang, C. Jin, X. Yu, L. Zuo
Journal: Annals of Oncology (2022)
454O A phase (Ph) I/II trial of the CXCR2 antagonist AZD5069 in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)
Authors: C. Guo, A. Sharp, U. Vogl, I. Colombo, A. Stathis, S. Jain, K. Chandran, C. Tiu, A. Paschalis, R.E. Matthews, I. Figueiredo, J. Rekowski, C. Yap, M. de los Dolores Fenor de la Maza, A. Turner, H.C. Badham, M. Parmar, F. Raynaud, A. Alimonti, J.S. de Bono
Journal: Annals of Oncology (2022)
780TiP A phase I dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB Antibody) alone and in combination with pembrolizumab in patients with advanced malignancies
Authors: E.P. Hamilton, I. Melero, I. Lugowska, A.M. Arance Fernandez, L. Vila Martinez, J.D. Powderly, M. Gutierrez, T. Serino, N. Mehta, I. Shapiro, K. Whalen, J. Michaelson, J. Jones, J.E. Janik, V. Moreno Garcia
Journal: Annals of Oncology (2022)
TCT-563 Sex Differences in Prevalence and Outcomes of the Different Endotypes of Chronic Coronary Syndrome in Patients With Angina Referred to the Cathlab
Authors: Caitlin Vink, Tim Van de Hoef, Joo Myung Lee, Coen Boerhout, Bon-Kwon Koo, Javier Escaned, Jan Piek, Tsunekazu Kakuta, Yolande Appelman, Guus De Waard
Journal: Journal of the American College of Cardiology (2022)
859P The influence of hematologic malignancies on response to immune checkpoint inhibition in patients with advanced melanoma
Authors: O.J. van Not, F. Van Den Eertwegh, J.B.A.G. Haanen, R.S. van Rijn, M. Aarts, F. Van den Berkmortel, C.U. Blank, M. Boers-Sonderen, J.W.B. de Groot, G. Hospers, E. Kapiteijn, M.M. De Meza, D. Piersma, M. Stevense-den Boer, A.A.M. Van der Veldt, G. Vreugdenhil, M. Wouters, W.A.M. Blokx, K.P.M. Suijkerbuijk
Journal: Annals of Oncology (2022)
1023P Relationship between 18F-FDG PET colonic uptake, resting energy expenditure and immune checkpoint inhibitors efficacy in metastatic non-small cell lung cancer (NSCLC) patients: Preliminary results of the MICROBIO-TEP study
Authors: J. Chen, L. Hirsch, D. Dudoignon, M. Tiako Meyo, J. Zerbit, J. Arrondeau, P. Boudou Rouquette, M. Wislez, J. Alexandre, F. Goldwasser, M. Wartski
Journal: Annals of Oncology (2022)
1017P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC)
Authors: Y. Yu, D. Huang, B. Gao, J. Zhao, Y. Hu, W. Zhuang, S. Kao, W. Xu, Y. Yao, T-Y. Yang, Y. Lee, J-S. Kim, H-S. Shiah, R. Wang, H. Zheng, W. Tan, R. Gao, H.R. Kim, S. Lu
Journal: Annals of Oncology (2022)
57P Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in advanced biliary tract cancer (BTC)
Authors: L. Antonuzzo, H. Takahashi, J.O. Park, A. Sookprasert, R. Gillmore, S-S. Yang, J.E. Cundom, M. Petrova, G.M. Vaccaro, M. Holmblad, J. Xiong, K. Heider, N. Rokutanda, D-Y. Oh
Journal: Annals of Oncology (2022)
500P The impact of COVID-19 on the management and outcome of oncology patients: The results of the Middle East and North African (MENA) COVID-19 and Cancer Registry (MCCR)
Authors: A.R. Jazieh, H. Abdel-Razeq, E.B. Köksoy, A. Bounedjar, A. Tafayli, E. Tashkandi, W. Jastaniah, J. Ansari, M.O. Alorabi, A.D. Darwish, A. Rabea, A.A.M. Alolayan, F. Ibnshamsa, H. Errihani, M. Alkaiyat, E. Garrett-Mayer, S.S. Bruinooge, F. Hussain, H. Tamim, K. AlKattan
Journal: Annals of Oncology (2022)
235P The impact of body mass index (BMI) on the progression-free survival of CDK4/6 inhibitors in metastatic breast cancer patients (MBC)
Authors: M. Artac, D. Cağlayan, M.Z. Koçak, C. Geredeli, A.M. Tatli, S. Sezgin Goksu, M. Karakurt Ery lmaz, M. Araz
Journal: Annals of Oncology (2022)
792MO Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable stage III melanoma
Authors: M. Lowe, M.L. Yushak, B. Olson, A. Mokhtari, A. Harutyunyan, K. Delman, D. Parker, E. Evans, T. Fisher, G. Lesinski, R. Kudchadkar
Journal: Annals of Oncology (2022)
736MO Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS)
Authors: C.K. Kyi, A. Spira, D.P. Carbone, M.L. Johnson, B.S. Henick, B. Johnson, H. Borghaei, A. Mahipal, J.R. Hecht, D. Catenacci, C-Y. Liao, A. Shergill, R. Memmott, C. Presley, J. Jaroslavsky, D. Schenk, K. Jooss, A.R. Ferguson, J.W. Goldman
Journal: Annals of Oncology (2022)
922P Automated and rapid KRAS mutation testing in non-small cell lung cancer
Authors: G. Recondo, S. Akselrad, F. Jauk, P. Teves, J. Pandolfi, L. Basbus, C.A. Franco Cortes, H. Garcia Rivello, R. Sanchez Marull, Y. Powazniak, J. Calderazzo, M.V. Bluthgen, S.N. Sena, A. Perfetti, P.P. Levit, N. Castagneris, M.M. Rizzo, L. Lupinacci, J.N. Minatta
Journal: Annals of Oncology (2022)
943P Association between event-free survival and overall survival following neoadjuvant therapy for non-small-cell lung cancer
Authors: G. Ostoros, M. Berktas, P. Chander, I. Diaz Perez, N.E. Georgoulia, R. Hettle, P. Morten, A-M. Couto, C. Eichinger, P. Field, B. Massuti Sureda
Journal: Annals of Oncology (2022)
464P Intra-patient (Pt) comparison from larotrectinib (Laro) clinical trials in tropomyosin receptor kinase (TRK) fusion cancer: An expanded dataset
Authors: A. Italiano, A.E. Drilon, L. Shen, D.S. Hong, C. van Tilburg, D.S.W. Tan, J.J. Lin, S. Kummar, F. Doz, B. Geoerger, M.S. Brose, A. Briggs, U.N. Lassen, G. Vassal, K.N. Keating, R. Norenberg, L. Dima, N. Brega, T. Laetsch, J. Garcia-Foncillas
Journal: Annals of Oncology (2022)
880P Phase II trial of the cyclin dependent kinase 4/6 inhibitor SHR6390 in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification
Authors: C. Shi, J. Houyu, R. Zhou, Y. Wu, H. Li, Y. Wang, S. Xu, Z. Gu, J. Li, Z. Zhang, G. Ren
Journal: Annals of Oncology (2022)
796P Neoadjuvant toripalimab plus axitinib in patients (pts) with resectable mucosal melanoma (MuM): Updated findings of a single-arm, phase II trial
Authors: C-L. Cui, Z. Li, N. Wu, M. Li, X. Chen, H. Zheng, M. Gao, D. Wang, B. Lian, X. Wang, H. Tian, L. Si, Z. Chi, X. Sheng, Y. Lai, T. Sun, Q. Zhang, Y. Kong, J. Guo
Journal: Annals of Oncology (2022)
982P Final results and biomarker analysis of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study
Authors: A. Nakamura, H. Kenmotsu, K. Sakai, K. Mori, T. Kato, K. Kirita, Y. Yoneshima, K. Azuma, K. Nishino, S. Teraoka, T. Shukuya, K. Masuda, H. Hayashi, R. Toyozawa, S. Miura, D. Fujimoto, K. Nakagawa, N. Yamamoto, K. Nishio, T. Takahashi
Journal: Annals of Oncology (2022)
1073P Relationship between basal metabolism, nivolumab clearance and survival in metastatic non-small cell lung cancer patients of the ELY study
Authors: A. Puszkiel, P. Boudou Rouquette, J. Arrondeau, M. Wislez, E. Fabre-Guillevin, G. Bianconi, X. Declèves, A. Jouinot, S. De Percin, J. Alexandre, F. Goldwasser, B. Blanchet
Journal: Annals of Oncology (2022)
248P Sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments
Authors: B. Xu, F. Ma, S. Wang, Z. Tong, W. Li, X. Wu, X. Wang, T. Sun, Y. Pan, H. Yao, X. Wang, T. Luo, J. Yang, X. Zeng, W. Zhao, X.J. Cong, J. Chen
Journal: Annals of Oncology (2022)
877P Characteristics of malignant cutaneous adnexal tumors in a single-institution study
Authors: E.C. Koch, M. Vilbert, T. Pimentel Muniz, D. Ghazarian, I. Hirsch, M.F. Silva Almeida Ribeiro, L. Mantle, D. Hogg, S. Saibil, A. Spreafico, M.O. Butler
Journal: Annals of Oncology (2022)
809P Outcomes of patients with resected stage III/IV acral or mucosal melanoma treated with adjuvant anti-PD-1 therapy
Authors: S.K. Jacques, J. McKeown, P. Grover, B. Park, A. Zaremba, F. Dimitriou, M.F. Harunal Rashid, K. Namikawa, M. Mooradian, J. Placzke, C. Allayous, I. Mehmi, D. DePalo, A. Wicky, J.K. Schwarze, Y. Nakamura, N. Benannoune, A.M. Menzies, S.N. Lo, M.S. Carlino
Journal: Annals of Oncology (2022)
895P Correlating peptidylglycine alpha-amidating monooxygenase (PAM) expression with clinicopathologic variables in gastrointestinal (GI) neuroendocrine tumors (NETs)
Authors: J. Sim, H. Marginean, A. Jirovec, M.M. Vickers, E.C. Marginean, T.R. Asmis, B. Marginean, R.A. Goodwin
Journal: Annals of Oncology (2022)
504P SARS-CoV-2 Omicron (B.1.1.529) variant infection leads to high morbidity and mortality in unvaccinated patients with cancer
Authors: D.J. Pinato, J. Aguilar-Company, A. Bertuzzi, G.H. Hanbury, M.D. Bower, R. Salazar, M. Lambertini, P. Pedrazzoli, A.J.X. Lee, A. Sinclair, S. Townsend, A. Plaja Salarich, A.R. Sita-Lumsden, U. Mukherjee, N. Diamantis, R. Sharkey, G. Gaidano, A. Gennari, J. Tabernero, A. Cortellini
Journal: Annals of Oncology (2022)
450O Initial monotherapy results of a phase I first-in-human study of ULK1/2 inhibitor DCC-3116 alone and in combination with MAPK pathway inhibition
Authors: A.W. Tolcher, D.S. Hong, A. Vandross, R. Amaravadi, C. Psoinos, D. Brennan, M.L. Sherman, R. Ruiz-Soto, L. Viswanathan, K. Sprott, F.J. Reu, C.D. Weekes
Journal: Annals of Oncology (2022)
762P Personalized immunotherapy with encapsulated cell technology: Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors
Authors: E. Fernandez, R. Vernet, E. Charrier, D.M. Migliorini, M. Urwyler, M-C. Belkouch, O. Von Rohr, V. Saingier, V. Ancrenaz, N. Grandjean, E. Lafferma, E. Lavalliere, O. Rubin, J. Villard, J.N. Grogg, N. Mach
Journal: Annals of Oncology (2022)
567P Phase Ib study of Intraperitoneal (IP) administration of nivolumab plus ipilimumab in patients with recurrent gynaecologic malignancies with peritoneal involvement
Authors: E. Hinchcliff, A. Mosely, S. Hull, S. Westin, A. Sood, K. Schmeler, J. Taylor, S. Huang, R. Sheth, K. Lu, A. Jazaeri
Journal: Annals of Oncology (2022)
42P Antitumor activity of zolbetuximab combined with chemotherapy and anti-mouse PD-1 antibody (anti-mPD-1) in a syngeneic mouse model and a virtual preclinical trial using a quantitative systems pharmacology (QSP) model
Authors: T. Nakayama, M. Oishi, J. Weng, K. Omori, C. Kwon, T. Nakazawa, T. Nishibata, F. Kinugasa, T. Yoshida, Y. Nagasaka
Journal: Annals of Oncology (2022)